GTBP Historical Financial Ratios
| GTBP Stock | USD 3.04 0.36 13.43% |
GT Biopharma is recently reporting on over 98 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.31 or Days Sales Outstanding of 54.84 will help investors to properly organize and evaluate GT Biopharma financial condition quickly.
GTBP |
About GTBP Financial Ratios Analysis
GT BiopharmaFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate GT Biopharma investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on GTBP financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across GT Biopharma history.
GT Biopharma Financial Ratios Chart
Add Fundamental
Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Effective Tax Rate
Effective Tax Rate is the average rate at which GT Biopharma pre-tax profits are taxed by the government. The effective tax rate is computed by dividing GT Biopharma total tax expenses by GT Biopharma earnings before taxes.Most ratios from GT Biopharma's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into GT Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GT Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.At this time, GT Biopharma's Intangibles To Total Assets are relatively stable compared to the past year. As of 12/11/2024, Current Ratio is likely to grow to 3.27, while Book Value Per Share is likely to drop 5.27.
| 2023 | 2024 (projected) | Payables Turnover | 0.002371 | 0.002253 | Days Of Inventory On Hand | 61.05 | 86.22 |
GT Biopharma fundamentals Correlations
Click cells to compare fundamentals
GT Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
GT Biopharma fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | (0.24) | (1.08) | 3.92 | 2.41 | 1.38 | 1.31 | |
| Book Value Per Share | (171.19) | (201.36) | 23.35 | 11.05 | 5.55 | 5.27 | |
| Free Cash Flow Yield | (0.79) | (0.23) | (0.18) | (0.54) | (0.86) | (0.9) | |
| Operating Cash Flow Per Share | (32.44) | (49.68) | (16.63) | (14.33) | (6.57) | (6.9) | |
| Pb Ratio | (0.24) | (1.08) | 3.92 | 2.41 | 1.38 | 1.31 | |
| Free Cash Flow Per Share | (32.44) | (49.68) | (16.63) | (14.33) | (6.57) | (6.9) | |
| Roic | 2.87 | 2.58 | (2.65) | (1.76) | (1.8) | (1.71) | |
| Net Income Per Share | (361.49) | (216.29) | (62.54) | (19.3) | (5.64) | (5.92) | |
| Cash Per Share | 0.25 | 36.24 | 34.07 | 15.54 | 10.37 | 9.85 | |
| Pocfratio | (1.27) | (4.35) | (5.5) | (1.85) | (1.16) | (1.22) | |
| Interest Coverage | (7.55) | (2.04) | (80.1) | (2.7K) | (3.1K) | (2.9K) | |
| Pfcf Ratio | (1.27) | (4.35) | (5.5) | (1.85) | (1.16) | (1.22) | |
| Roe | 2.13 | 1.08 | (2.68) | (1.75) | (1.02) | (1.07) | |
| Ev To Operating Cash Flow | (4.92) | (7.25) | (4.93) | (1.49) | (1.05) | (1.1) | |
| Pe Ratio | (0.11) | (1.0) | (1.46) | (1.38) | (1.36) | (1.29) | |
| Return On Tangible Assets | (102.97) | (5.58) | (1.82) | (1.23) | (0.54) | (0.57) | |
| Ev To Free Cash Flow | (4.92) | (7.25) | (4.93) | (1.49) | (1.05) | (1.1) | |
| Earnings Yield | (8.75) | (1.0) | (0.68) | (0.73) | (0.74) | (0.77) | |
| Net Debt To E B I T D A | (0.043) | (1.16) | (0.84) | (0.17) | (0.15) | (0.16) | |
| Current Ratio | 0.0139 | 0.16 | 3.14 | 3.35 | 2.12 | 3.27 | |
| Tangible Book Value Per Share | (171.19) | (201.36) | 23.35 | 11.05 | 5.55 | 5.27 | |
| Graham Number | 1.2K | 987.07 | 181.24 | 69.26 | 26.54 | 25.21 | |
| Shareholders Equity Per Share | (169.69) | (200.2) | 23.35 | 11.05 | 5.55 | 5.27 | |
| Debt To Equity | (0.69) | (0.9) | 0.001415 | 0.009374 | 0.007758 | 0.008146 |
Pair Trading with GT Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if GT Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in GT Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against GTBP Stock
| 0.85 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.74 | LLY | Eli Lilly | PairCorr |
| 0.71 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.62 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.51 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to GT Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace GT Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back GT Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling GT Biopharma to buy it.
The correlation of GT Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as GT Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if GT Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for GT Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.